)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
HUTCHMED (China) (HCM) investor relations material
HUTCHMED (China) H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary7 Aug, 2025
Executive summary
Net income reached $455 million in H1 2025, mainly from a $609 million gain on partial SHPL divestment, with cash and short-term investments at $1.36 billion as of June 30, 2025.
Global commercial success for Zecla/FRUZAQLAⓇ, with 25% year-over-year growth and launches in over 30 countries.
Oncology/Immunology revenue declined 15% year-over-year to $143.5 million, with total revenue down 9–10% to $277.7–$278 million.
Advanced late-stage pipeline and ATTC platform, with first clinical trial initiation expected by late 2025.
Key product approvals and launches included new indications for savolitinib/ORPATHYSⓇ, fruquintinib/ELUNATEⓇ, and TAZVERIKⓇ in China.
Financial highlights
Net income attributable to shareholders was $455 million for H1 2025, up from $25.8 million in H1 2024, driven by the SHPL divestment gain.
Total revenue for H1 2025 was $277.7–$278 million, down 9–10% year-over-year; Oncology/Immunology revenue was $143.5 million, down 15%.
R&D investments totaled $72 million, with operating expenses and S&A costs reduced year-over-year.
Cash and short-term investments increased to $1.36 billion, with net cash inflows of $519.1 million (non-GAAP).
EPS rose to $0.53 per share ($2.65 per ADS) from $0.03 per share ($0.15 per ADS) in H1 2024.
Outlook and guidance
Full-year 2025 Oncology/Immunology revenue guidance revised to $270–$350 million due to milestone phasing and regulatory review delays.
Anticipate improved sales growth in H2 2025, supported by new approvals and expanded reimbursement.
Multiple NDA submissions and clinical trial readouts expected in the next 12 months.
Strong cash position will be leveraged for ATTC global development and acquisitions.
ATTC target disclosure & early combo strategy?
China sales decline drivers & recovery sustainability?
Sovleplenib NDA delay & new entity timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next HUTCHMED (China) earnings date
Status Update31 Oct, 2025
Next HUTCHMED (China) earnings date
Status Update31 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
HUTCHMED Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company integrates innovative science and clinical expertise to develop a robust pipeline of therapies, leveraging its research and development capabilities in China and internationally. HUTCHMED markets its products in various regions and collaborates with global pharmaceutical partners for distribution and development. The company is headquartered in Hong Kong, China, and its shares are listed on the NASDAQ and the London Stock Exchange (LSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage